CLINICAL RESULTS OF BIOSLIFE

Dr. Peter Verdegem,
Unicity Chief Science Officer

Viscous soluble fiber combined with phytosterols and policosanol reduces
LDL cholesterol and increases HDL cholesterol in hypercholesterolemia

Peter J.E. Verdegem, Ph.D.*, Research and Development Department, Unicity International, 1201 North 800 East, Orem, UT 84097

 

ABSTRACT

 

Introduction

This pilot study investigates the efficacy of a combination of
neutraceuticals in improving lipid levels. The tested product combines viscous soluble fiber with phytosterols, olicosanol, and an extract of Chrysanthemum morifolium. All four ingredients have been shown to have cholesterol lowering potential, but all through different biological mechanisms. The test product is the first to combine these four cholesterol lowering mechanisms in one product.

 

Materials and Methods

Twenty five subjects completed an 8-week open label study design. The product was taken twice daily before the main meals. Fasting lipid panels were measured at baseline, 4, and 8 weeks.

 

Results

The total cholesterol levels were reduced 8.2% (p<0.05) after 8 weeks, and 10.7% (p<0.01) in a subgroup of subjects with TC levels > 200 mg/dL at baseline.

LDL-cholesterol was reduced 4.8% (p<0.01) and 24.5% (p<0.001), and 30.6% (p<0.00001) in sub groups of subjects having baseline LDL-cholesterol levels > 130 and > 160 mg/dL, respectively.

HDL-cholesterol levels were increased 8.3% (p<0.05).

 

Conclusion

This neutraceutical combination therapy is promising as a first line intervention, and may serve as an adjunct therapy to pharmaceutical lipid lowering prescription therapy.

 

Continue:

1. Introduction

2. Materials and Methods

3. Results

4. Discussion

5. Conclusion and Table